Neurogene Inc. Files 8-K with Regulatory Updates
Ticker: NGNE · Form: 8-K · Filed: Jun 30, 2025 · CIK: 1404644
Sentiment: neutral
Topics: 8-K, regulatory-disclosure, financial-reporting
TL;DR
Neurogene Inc. filed an 8-K on 6/30/25 covering Reg FD and financials. Formerly Neoleukin.
AI Summary
Neurogene Inc. filed an 8-K on June 30, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, and AQUINOX PHARMACEUTICALS (USA) INC, is headquartered in New York, NY.
Why It Matters
This filing provides essential updates on Neurogene Inc.'s regulatory compliance and financial reporting, which are crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure and does not appear to contain any new material adverse information.
Key Players & Entities
- Neurogene Inc. (company) — Registrant
- Neoleukin Therapeutics, Inc. (company) — Former Company Name
- AQUINX PHARMACEUTICALS, INC (company) — Former Company Name
- AQUINX PHARMACEUTICALS (USA) INC (company) — Former Company Name
- June 30, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Neurogene Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits as of June 30, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on June 30, 2025.
What is Neurogene Inc.'s principal executive office address?
Neurogene Inc.'s principal executive office is located at 535 W 24th Street, 5th Floor, New York, NY 10011.
What were some of Neurogene Inc.'s former company names?
Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., AQUINOX PHARMACEUTICALS, INC, and AQUINOX PHARMACEUTICALS (USA) INC.
What is Neurogene Inc.'s fiscal year end?
Neurogene Inc.'s fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 30, 2025 regarding Neurogene Inc. (NGNE).